Democratic president hopeful Bernie Sanders took aim at the pharmaceutical industry with a new bill that would provide the government with negotiating power, allow the import of lower-cost drugs from Canada, and requires reporting of information that affects drug pricing.
With the American public unhappy with the high cost of drugs, it was expected that prescription drugs would be an important issue for the 2016 presidential campaign. Democratic hopeful Senator Bernie Sanders (I-VT) is taking the first shot with a bill to battle rising prices.
Sanders and Representative Elijah Cummings (D-MD) rolled out their drug pricing bill, the Prescription Drug Affordability Act of 2015, which includes tactics like government power to directly negotiate drug prices and full disclosure of R&D and manufacturing costs, profits, and pricing in other countries.
“In the richest country in the history of the world, Americans should not have to live in fear that they will die because they cannot afford to take the life-saving medication they need,” Sanders said in a press conference.
The bill would allow US residents to import lower-cost medications from Canada, close the Medicare Part D donut hole for brand and generic drugs by 2017, restore the minimum rebate on drugs covered under Medicare Part D for low-income Medicare beneficiaries, prohibit anti-competitive arrangements between brand and generic drug makers, and require pharmaceutical companies to publicly report information that affects drug pricing.
The bill is cosponsored by Senator Al Franken (D-MN), and supported by the Alliance for Retired Americans, Social Security Works, the National Committee to Preserve Social Security and Medicare, National Center for Health Research, Public Citizen, Association of Clinicians for the Underserved, and RxRights.
Sanders acknowledged that passing the legislation will be difficult, and said he was unable to recall at time when the prescription drug industry lost a battle on Capitol Hill.
“But at a time when a huge majority of the American people want us to take action, when 74 percent of Republicans and 93 percent of Democrats, want the federal government to negotiate with the drug companies top lower prices, the time has come to say enough is enough,” he said.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More